CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Altimmune's Pemvidutide Reduces Liver Fat in 48-Week Phase 2b MASH Trial

By Public Technologies
  • Altimmune announced publication of 48-week IMPACT Phase 2b pemvidutide results in MASH in The Lancet Gastroenterology & Hepatology.
  • Findings previously presented at The Liver Meeting showed significant improvements versus placebo in noninvasive measures of liver fat, inflammation and fibrosis.
  • Treatment also produced significant weight loss, with generally favorable tolerability.
  • The results support the ongoing PERFORMA Phase 3 trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120715PRIMZONEFULLFEED9875986) on November 12, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk